IPO
WuXi Biologics (Cayman) Inc. announced its unaudited interim results for the six months ended June 30, 2019.
Sernova Corp., a clinical-stage regenerative medicine company, is pleased to announce that it has completed a first closing of $2,333,500 of its non-brokered private placement, of which $64,000 was closed under the “Existing Shareholder Exemption.”
The company is seeking the funds to continue to drive the development of its lead candidates, nirogacestat, a gamma-secretase inhibitor for the treatment of desmoid tumors and PD-0325901, a MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas.
Auris Medical Holding Ltd. provided a business update and announced financial results for the first half of the 2019 financial year ended June 30, 2019.
InflaRx reported financial and operating results for the second quarter ended June 30, 2019.
Evotec SE reported financial results and corporate updates for the first half of 2019.
Company Outlines Roadmap to Develop Successful Therapies for Neurodegenerative Diseases Based on its Broad Anti-Tau Clinical Pipeline
HOOKIPA Pharma Inc. reported recent clinical progress highlights and financial results for the second quarter ended June 30, 2019.
Adrenomed AG, the vascular integrity company, announced its participation at four upcoming conferences in Europe.
Microbix Biosystems Inc. reports results for its third quarter and nine months of fiscal 2019, the three-month and nine-month periods ending June 30, 2019 (“Q3" & “YTD”), with record YTD sales, strong YTD sales growth, improving percentage gross margin, and progress on its strategic goals.
PRESS RELEASES